<?xml version="1.0" encoding="UTF-8" ?>
<modsCollection xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://www.loc.gov/mods/v3" xmlns:slims="http://senayan.diknas.go.id" xsi:schemaLocation="http://www.loc.gov/mods/v3 http://www.loc.gov/standards/mods/v3/mods-3-3.xsd">
<mods version="3.3" ID="2350">
<titleInfo>
<title>European Journal of Pharmaceutical Sciences 1 May 2023</title>
</titleInfo>
<typeOfResource manuscript="yes" collection="yes">mixed material</typeOfResource>
<genre authority="marcgt">bibliography</genre>
<originInfo>
<place><placeTerm type="text"></placeTerm></place>
<publisher></publisher>
<dateIssued>2023</dateIssued>
<issuance>monographic</issuance>
<edition>1 May 2023</edition>
</originInfo>
<language>
<languageTerm type="code">id</languageTerm>
<languageTerm type="text">Indonesia</languageTerm>
</language>
<physicalDescription>
<form authority="gmd">Jurnal</form>
<extent></extent>
</physicalDescription>
<note>ABSTRACT
Bilayer tablets offer various drug release profiles for individual drugs incorporated in each layer of a bilayer

tablet, which is rarely achievable by conventional tablets. These tablets also help avoid physicochemical in-
compatibilities between drugs and excipients. Successful manufacturing of such more complex dosage forms

depends upon screening of material attributes of API and excipients as well as optimization of processing pa-
rameters of individual unit operations of the manufacturing process that must be strictly monitored and

controlled to obtain an acceptable drug product quality and performance in order to achieve safety and efficacy
per regulatory requirements. Optimizing formulation attributes and manufacturing processes during critical
stages, such as blending, granulation, pre-compression, and main compression, can help avoid problems such as
weight variation, segregation, and delamination of individual layers, which are frequently faced during the
production of bilayer tablets.
The main objective of this review is to establish the basis for the implementation of Quality by Design (QbD)

system principles for the design and development of bilayer tablets, encompassing the preliminary and sys-
tematic risk assessment of critical material attributes (CMAs) and critical process parameters (CPPs) with respect

to in-process and finished product critical quality attributes (CQAs). Moreover, the applicability of the QbD
methodology based on its purpose is discussed and complemented with examples of bilayer tablet technology.</note>
<subject authority=""><topic>Weight variation</topic></subject>
<subject authority=""><topic>Delamination</topic></subject>
<subject authority=""><topic>Bilayer tablet</topic></subject>
<classification></classification><identifier type="isbn"></identifier><location>
<physicalLocation>PERPUSTAKAAN SEKOLAH TINGGI ILMU KESEHATAN SAMARINDA REPOSITORY</physicalLocation>
<shelfLocator></shelfLocator>
<holdingSimple>
<copyInformation>
<numerationAndChronology type="1">JIN0133</numerationAndChronology>
<sublocation>Perpus.Akfarsam (Jurnal Farmasi Internasional)</sublocation>
<shelfLocator>615 ASI</shelfLocator>
</copyInformation>
</holdingSimple>
</location>
<slims:digitals>
<slims:digital_item id="2222" url="https://drive.google.com/file/d/192W0J8VVZORNplZ-qJUeCOiMHIZG1uQd/view?usp=sharing" path="/https://drive.google.com/file/d/192W0J8VVZORNplZ-qJUeCOiMHIZG1uQd/view?usp=sharing" mimetype="text/uri-list">1 May 2023</slims:digital_item>
</slims:digitals><slims:image>1_May_2023.jpeg.jpeg</slims:image>
<recordInfo>
<recordIdentifier>2350</recordIdentifier>
<recordCreationDate encoding="w3cdtf">2026-07-13 07:25:16</recordCreationDate>
<recordChangeDate encoding="w3cdtf">2026-07-13 07:31:26</recordChangeDate>
<recordOrigin>machine generated</recordOrigin>
</recordInfo></mods></modsCollection>